Edward Agyare to Pancreatic Neoplasms
This is a "connection" page, showing publications Edward Agyare has written about Pancreatic Neoplasms.
Connection Strength
3.201
-
Inkoom A, Ndemazie NB, Smith T, Frimpong E, Bulusu R, Poku R, Zhu X, Han B, Trevino J, Agyare E. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer. 2023 May 13; 23(1):435.
Score: 0.825
-
Ndemazie NB, Bulusu R, Zhu XY, Frimpong EK, Inkoom A, Okoro J, Ebesoh D, Rogers S, Han B, Agyare E. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. Int J Mol Sci. 2023 Feb 21; 24(5).
Score: 0.812
-
Ndemazie NB, Inkoom A, Ebesoh D, Bulusu R, Frimpong E, Trevino J, Han B, Zhu X, Agyare E. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. BMC Cancer. 2022 Dec 22; 22(1):1345.
Score: 0.803
-
Affram K, Udofot O, Singh M, Krishnan S, Reams R, Rosenberg J, Agyare E. Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. PLoS One. 2017; 12(9):e0185116.
Score: 0.558
-
Telisnor G, DeRemer DL, Frimpong E, Agyare E, Allen J, Ricks-Santi L, Han B, George T, Rogers SC. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. J Natl Med Assoc. 2023 Apr; 115(2):164-174.
Score: 0.203